Atlas Trials

A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

Clinical trial NCT02491099 · RECRUITING

Trial details

NCT number
NCT02491099
Sponsor
Yale University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HER2/Neu+ Uterine Serous Carcinoma
Start date
2015-06-01
Primary completion
2026-12-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.